8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 5, 2026·SEC
Material company update
Jan 23, 2026·SEC
NextCure, Inc.(NXTC)Earnings, Financials & Key Ratios
NXTC•NASDAQ
$10.18
$27M mkt cap·Price updated May 7, 2026
AboutNextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.Show more
- Revenue$0
- EBITDA-$55M+2.6%
- Net Income-$56M-0.3%
- EPS (Diluted)-19.65+17.7%
- ROE-111.23%-79.8%
- ROIC-152.15%-157.4%
- Debt/Equity0.12+30.6%
NXTC Key Insights
NextCure, Inc. (NXTC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.8x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 22.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
NXTC Price & Volume
NextCure, Inc. (NXTC) stock price & volume — 10-year historical chart
Loading chart...
NXTC Growth Metrics
NextCure, Inc. (NXTC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-10.38%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM10.19%
Return on Capital
10 Years-47.68%
5 Years-55.04%
3 Years-70.56%
Last Year-103.9%
NXTC Peer Comparison
NextCure, Inc. (NXTC) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 280.32M | 2.43 | -2.11 | -51.24% | -20.51% | -65.79% | 0.38 | |
 RCUS | 2.5B | 24.80 | -7.54 | -4.26% | -156.36% | -68.97% | 0.16 | |
 AGEN | 132.45M | 3.75 | -1102.94 | 10.37% | 0.1% | |||
 IMVT | 5.53B | 27.22 | -9.97 | -47.07% | 0.00 | |||
 TGTX | 6.87B | 43.03 | 15.53 | 87.32% | 65.95% | 87.36% | 0.40 | |
 KYMR | 6.91B | 84.63 | -22.94 | -16.72% | -6.12% | -25.02% | 0.05 | |
 INCY | 19.53B | 97.77 | 15.25 | 21.22% | 26.71% | 29.31% | 0.01 | |
 EXEL | 11.74B | 46.21 | 16.62 | 6.98% | 35.08% | 40.21% | 0.08 |
Compare NXTC vs Peers
NextCure, Inc. (NXTC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NXTC Income Statement
NextCure, Inc. (NXTC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 6.35M | 22.38M | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | 252.58% | -100% | - | - | - | - | - |
| Cost of Goods Sold | 582K | 1.68M | 34.22M | 46.55M | 0 | 0 | 0 | 0 | 2.19M | 365K |
| COGS % of Revenue | - | - | 539.09% | 208.03% | - | - | - | - | - | - |
| Gross Profit | -582K▲ 0% | -1.68M▼ 188.1% | -27.87M▼ 1561.8% | -24.18M▲ 13.3% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -2.19M▲ 0% | -365K▲ 0% |
| Gross Margin % | - | - | -439.09% | -108.03% | - | - | - | - | - | - |
| Gross Profit Growth % | - | -188.14% | -1561.84% | 13.25% | 100% | - | - | - | - | - |
| Operating Expenses | 15.55M | 23.2M | 9.61M | 17.05M | 70.77M | 75.91M | 67.64M | 59.75M | 55.43M | 55.73M |
| OpEx % of Revenue | - | - | 151.46% | 76.19% | - | - | - | - | - | - |
| Selling, General & Admin | 2.6M | 3.41M | 9.61M | 17.05M | 20.57M | 21.71M | 19.71M | 15.72M | 12.69M | 12.23M |
| SG&A % of Revenue | - | - | 151.46% | 76.19% | - | - | - | - | - | - |
| Research & Development | 12.95M | 19.79M | 34.22M | 46.55M | 50.19M | 54.2M | 47.93M | 41.49M | 44.92M | 43.5M |
| R&D % of Revenue | - | - | 539.09% | 208.03% | - | - | - | - | - | - |
| Other Operating Expenses | 80K | 397K | -34.22M | -46.55M | 0 | 0 | 0 | 2.54M | -2.19M | 0 |
| Operating Income | -15.55M▲ 0% | -23.2M▼ 49.2% | -37.48M▼ 61.6% | -41.23M▼ 10.0% | -70.77M▼ 71.7% | -75.91M▼ 7.3% | -67.64M▲ 10.9% | -59.75M▲ 11.7% | -57.62M▲ 3.6% | -56.1M▲ 0% |
| Operating Margin % | - | - | -590.55% | -184.22% | - | - | - | - | - | - |
| Operating Income Growth % | - | -49.18% | -61.59% | -9.99% | -71.66% | -7.27% | 10.9% | 11.66% | 3.57% | - |
| EBITDA | -14.97M | -21.52M | -34.79M | -37.81M | -66.59M | -71.78M | -63.95M | -56.88M | -55.43M | -54.57M |
| EBITDA Margin % | - | - | -548.2% | -168.97% | - | - | - | - | - | - |
| EBITDA Growth % | - | -43.78% | -61.69% | -8.67% | -76.1% | -7.8% | 10.91% | 11.05% | 2.55% | -8.41% |
| D&A (Non-Cash Add-back) | 582K | 1.68M | 2.69M | 3.41M | 4.18M | 4.12M | 3.68M | 2.87M | 2.19M | 1.53M |
| EBIT | -15.44M | -22.77M | -37.48M | -41.23M | -70.77M | -75.91M | -67.64M | -57.21M | -57.62M | -45.67M |
| Net Interest Income | 0 | 0 | -205.25K | -178.45K | -75.68K | 1.17M | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 3.75K | 4.55K | 1.32K | 1.17M | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 209K | 183K | 77K | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 80K | 397K | 3.75M | 4.62M | 1.38M | 1.18M | 4.91M | 4.09M | 1.77M | 1.44M |
| Pretax Income | -15.47M▲ 0% | -22.8M▼ 47.4% | -33.74M▼ 48.0% | -36.6M▼ 8.5% | -69.39M▼ 89.6% | -74.73M▼ 7.7% | -62.72M▲ 16.1% | -55.65M▲ 11.3% | -55.84M▼ 0.3% | -54.66M▲ 0% |
| Pretax Margin % | - | - | -531.54% | -163.57% | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -15.47M▲ 0% | -22.8M▼ 47.4% | -33.74M▼ 48.0% | -36.6M▼ 8.5% | -69.39M▼ 89.6% | -74.73M▼ 7.7% | -62.72M▲ 16.1% | -55.65M▲ 11.3% | -55.84M▼ 0.3% | -54.66M▲ 0% |
| Net Margin % | - | - | -531.54% | -163.57% | - | - | - | - | - | - |
| Net Income Growth % | - | -47.39% | -47.98% | -8.5% | -89.57% | -7.7% | 16.07% | 11.27% | -0.34% | -10.38% |
| Net Income (Continuing) | -15.47M | -22.8M | -33.74M | -36.6M | -69.39M | -74.73M | -62.72M | -55.65M | -55.84M | -54.66M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -8.17▲ 0% | -12.04▼ 47.4% | -25.79▼ 114.2% | -15.95▲ 38.1% | -30.15▼ 89.0% | -32.32▼ 7.2% | -27.04▲ 16.3% | -23.88▲ 11.7% | -19.65▲ 17.7% | -10.43▲ 0% |
| EPS Growth % | - | -47.39% | -114.15% | 38.15% | -89% | -7.2% | 16.35% | 11.68% | 17.71% | 10.19% |
| EPS (Basic) | -8.17 | -12.04 | -25.79 | -15.95 | -30.15 | -32.32 | -27.04 | -23.88 | -19.65 | - |
| Diluted Shares Outstanding | 1.89M | 1.89M | 1.31M | 2.29M | 2.3M | 2.31M | 2.32M | 2.33M | 2.84M | 5.24M |
| Basic Shares Outstanding | 1.89M | 1.89M | 1.31M | 2.29M | 2.3M | 2.31M | 2.32M | 2.33M | 2.84M | 5.24M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
NXTC Balance Sheet
NextCure, Inc. (NXTC) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 9.42M | 135.78M | 340M | 287.98M | 227.82M | 163.98M | 112.72M | 71.81M | 43.75M | 31.74M |
| Cash & Short-Term Investments | 8.43M | 135.17M | 334.61M | 283.45M | 219.59M | 159.91M | 108.3M | 68.62M | 41.82M | 29.74M |
| Cash Only | 8.43M | 135.17M | 34.09M | 32.77M | 12.34M | 26.63M | 13.08M | 27.73M | 25.98M | 15.17M |
| Short-Term Investments | 0 | 0 | 300.51M | 250.68M | 207.25M | 133.28M | 95.22M | 40.89M | 15.84M | 14.58M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 700K | 800K | 300K | 100K | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | -700K | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 860K | 460K | 1.71M | 1.71M | 39K | 4.07M | 3.63M | 2.89M | 1.83M | 2M |
| Total Non-Current Assets | 10.05M | 11.84M | 16.17M | 18.67M | 14.57M | 20.18M | 15.31M | 9.05M | 6.44M | 6.24M |
| Property, Plant & Equipment | 10.02M | 11.41M | 12.09M | 15.81M | 13.99M | 16.91M | 13.43M | 8.72M | 5.89M | 5.39M |
| Fixed Asset Turnover | - | - | 0.52x | 1.42x | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 3.33M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 26K | 436K | 750K | 2.86M | 577K | 1.73M | 1.88M | 332K | 546K | 2.5M |
| Total Assets | 19.47M▲ 0% | 147.63M▲ 658.4% | 356.17M▲ 141.3% | 306.64M▼ 13.9% | 242.39M▼ 21.0% | 184.16M▼ 24.0% | 128.04M▼ 30.5% | 80.86M▼ 36.8% | 50.18M▼ 37.9% | 37.98M▲ 0% |
| Asset Turnover | - | - | 0.02x | 0.07x | - | - | - | - | - | 0.00x |
| Asset Growth % | - | 658.35% | 141.26% | -13.9% | -20.96% | -24.02% | -30.48% | -36.85% | -37.94% | -191.04% |
| Total Current Liabilities | 3.12M | 10.3M | 15.04M | 10.32M | 6.61M | 9.13M | 6.88M | 9.57M | 10.57M | 6.89M |
| Accounts Payable | 1.14M | 2.48M | 1.86M | 3.9M | 1.94M | 4.27M | 2.33M | 5.35M | 2.01M | 3.07M |
| Days Payables Outstanding | 715.58 | 540.43 | 19.85 | 30.59 | - | - | - | - | 335.93 | 2.5K |
| Short-Term Debt | 400K | 387K | 1.67M | 1.67M | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | -504K | 4.99M | 6.43M | 130K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 19K | 28K | 234K | 13K | 2.92M | 2.7M | 113K | 1.67M | 8.55M | 6.89M |
| Current Ratio | 3.02x | 13.19x | 22.60x | 27.89x | 34.48x | 17.97x | 16.38x | 7.50x | 4.14x | 4.14x |
| Quick Ratio | 3.02x | 13.19x | 22.60x | 27.89x | 34.48x | 18.04x | 16.38x | 7.50x | 4.14x | 4.14x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 40.76M | 184.27M | 19.64M | 2.6M | 2.39M | 7.5M | 6.73M | 5.81M | 4.67M | 4.37M |
| Long-Term Debt | 460K | 73K | 3.33M | 1.81M | 0 | 0 | 0 | 0 | 4.15M | 3.88M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 6.61M | 5.95M | 5.15M | 0 | 8.81M |
| Deferred Tax Liabilities | 0 | 0 | 0 | -15.95M | 0 | 1.54M | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 40.3M | 162.47M | 359K | 792K | 2.39M | 899K | 785K | 661K | 526K | 2.17M |
| Total Liabilities | 43.88M | 194.57M | 34.68M | 12.92M | 9M | 16.63M | 13.62M | 15.39M | 15.24M | 11.26M |
| Total Debt | 964K | 587K | 5.13M | 3.47M | 0 | 7.12M | 6.61M | 5.95M | 4.15M | 3.88M |
| Net Debt | -7.46M | -134.59M | -28.96M | -29.3M | -12.34M | -19.51M | -6.48M | -21.78M | -21.83M | -11.29M |
| Debt / Equity | - | - | 0.02x | 0.01x | - | 0.04x | 0.06x | 0.09x | 0.12x | 0.12x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.07x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.21x |
| Interest Coverage | - | - | -179.34x | -225.27x | -919.03x | - | - | - | - | - |
| Total Equity | -24.41M▲ 0% | -46.94M▼ 92.3% | 321.48M▲ 784.8% | 293.72M▼ 8.6% | 233.39M▼ 20.5% | 167.53M▼ 28.2% | 114.42M▼ 31.7% | 65.47M▼ 42.8% | 34.94M▼ 46.6% | 26.72M▲ 0% |
| Equity Growth % | - | -92.3% | 784.82% | -8.64% | -20.54% | -28.22% | -31.7% | -42.78% | -46.63% | -230.48% |
| Book Value per Share | -12.90 | -24.80 | 245.79 | 128.02 | 101.41 | 72.46 | 49.33 | 28.09 | 12.29 | 5.10 |
| Total Shareholders' Equity | -24.41M | -46.94M | 321.48M | 293.72M | 233.39M | 167.53M | 114.42M | 65.47M | 34.94M | 26.72M |
| Common Stock | 11K | 11K | 27K | 28K | 28K | 28K | 28K | 28K | 4K | 4K |
| Retained Earnings | -24.5M | -47.3M | -81.03M | -117.64M | -187.03M | -261.76M | -324.48M | -380.14M | -435.98M | -445.78M |
| Treasury Stock | -75K | -332K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -792K | -2.47M | -38K | 779K | -663K | -1.49M | -222K | 4K | 21K | -2K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NXTC Cash Flow Statement
NextCure, Inc. (NXTC) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -12.51M | 7.99M | -35.62M | -44.95M | -57.24M | -53.89M | -52.97M | -40.8M | -49.61M | -49.61M |
| Operating CF Margin % | - | - | -561.26% | -200.88% | - | - | - | - | - | - |
| Operating CF Growth % | - | 163.86% | -545.73% | -26.19% | -27.34% | 5.87% | 1.69% | 22.97% | -21.59% | -99.5% |
| Net Income | -15.47M | -22.8M | -33.74M | -36.6M | -69.39M | -74.73M | -62.72M | -55.65M | -55.84M | -54.66M |
| Depreciation & Amortization | 582K | 1.68M | 2.69M | 3.41M | 7.2M | 4.12M | 3.68M | 2.87M | 1.7M | 1.56M |
| Stock-Based Compensation | 75K | 263K | 1.89M | 7.91M | 10.29M | 9.51M | 8.19M | 6.33M | 2.99M | 1.97M |
| Deferred Taxes | 0 | 0 | -7.26M | -12.7M | -23.74M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.24M | 3.21M | 7.26M | 12.7M | 23.74M | 3.49M | -183K | 1.12M | 587K | -3.74M |
| Working Capital Changes | 2.3M | 28.85M | -6.46M | -19.68M | -5.34M | 3.73M | -1.94M | 4.53M | 954K | 4.89M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 767K | 1.34M | -622K | 2.04M | -1.96M | 2.33M | -1.94M | 3.02M | -3.34M | 334K |
| Cash from Investing | -8.65M | -3.06M | -303.92M | 43.52M | 36.6M | 67.98M | 39.27M | 55.31M | 25.56M | 19.76M |
| Capital Expenditures | -8.65M | -3.06M | -3.37M | -7.13M | -2.36M | -2.12M | -820K | -474K | 0 | 0 |
| CapEx % of Revenue | - | - | 53.11% | 31.87% | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | -50.66K | -38.96K | -70.09K | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 50.66K | 38.96K | 70.09K | 0 | 0 | 0 | 0 |
| Cash from Financing | 24.86M | 121.42M | 243.04M | -1.42M | -3.27M | 200K | 154K | 144K | 22.31M | 23.56M |
| Debt Issued (Net) | -140K | -400K | 4.54M | -1.53M | -3.47M | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 25M | 122.23M | 238.5M | 112K | 208K | 200K | 154K | 39K | 22.31M | 22.31M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -410K | 0 | 0 | 0 | 0 | 0 | 105K | 0 | 1.25M |
| Net Change in Cash | 3.69M▲ 0% | 126.35M▲ 3320.3% | -96.5M▼ 176.4% | -2.85M▲ 97.1% | -23.91M▼ 740.1% | 14.29M▲ 159.8% | -13.55M▼ 194.8% | 14.64M▲ 208.1% | -1.75M▼ 111.9% | -6.66M▲ 0% |
| Free Cash Flow | -21.17M▲ 0% | 4.93M▲ 123.3% | -38.99M▼ 891.1% | -52.09M▼ 33.6% | -59.6M▼ 14.4% | -56M▲ 6.0% | -53.79M▲ 3.9% | -41.28M▲ 23.3% | -49.61M▼ 20.2% | -49.98M▲ 0% |
| FCF Margin % | - | - | -614.37% | -232.76% | - | - | - | - | - | - |
| FCF Growth % | - | 123.29% | -891.11% | -33.57% | -14.43% | 6.04% | 3.94% | 23.26% | -20.19% | -20.06% |
| FCF per Share | -11.18 | 2.60 | -29.81 | -22.70 | -25.90 | -24.22 | -23.19 | -17.71 | -17.45 | -17.45 |
| FCF Conversion (FCF/Net Income) | 0.81x | -0.35x | 1.06x | 1.23x | 0.82x | 0.72x | 0.84x | 0.73x | 0.89x | 0.91x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NXTC Key Ratios
NextCure, Inc. (NXTC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -24.58% | -11.9% | -26.33% | -37.28% | -44.49% | -61.87% | -111.23% | -186.96% |
| Return on Invested Capital (ROIC) | - | -50.65% | -11.1% | -21.86% | -30.85% | -39.64% | -59.1% | -152.15% | -152.15% |
| Gross Margin | - | -439.09% | -108.03% | - | - | - | - | - | - |
| Net Margin | - | -531.54% | -163.57% | - | - | - | - | - | - |
| Debt / Equity | - | 0.02x | 0.01x | - | 0.04x | 0.06x | 0.09x | 0.12x | 0.12x |
| Interest Coverage | - | -179.34x | -225.27x | -919.03x | - | - | - | - | - |
| FCF Conversion | -0.35x | 1.06x | 1.23x | 0.82x | 0.72x | 0.84x | 0.73x | 0.89x | 0.91x |
| Revenue Growth | - | - | 252.58% | -100% | - | - | - | - | - |
NXTC SEC Filings & Documents
NextCure, Inc. (NXTC) SEC filings — annual & quarterly reports (10-K, 10-Q)
NXTC Frequently Asked Questions
NextCure, Inc. (NXTC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
NextCure, Inc. (NXTC) grew revenue by 0.0% over the past year. Growth has been modest.
NextCure, Inc. (NXTC) reported a net loss of $54.7M for fiscal year 2025.
Dividend & Returns
NextCure, Inc. (NXTC) has a return on equity (ROE) of -111.2%. Negative ROE indicates the company is unprofitable.
NextCure, Inc. (NXTC) had negative free cash flow of $50.0M in fiscal year 2025, likely due to heavy capital investments.
Explore More NXTC
NextCure, Inc. (NXTC) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates